Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.

Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB, Wren JD, Niedernhofer LJ, Robbins PD, Kirkland JL. · 2016

Read Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. by Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB, Wren JD, Niedernhofer LJ, Robbins PD, Kirkland JL. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4854923.txt.

Description

Yi Zhu and co-authors identified navitoclax in 2016 as a drug that kills aged, worn-out cells called senescent cells. Clearing such cells extends healthy life in mice. Senescent cells resist death through survival paths, and two earlier drugs that block those paths were already known. The team tested navitoclax, a blocker of the Bcl-2 survival protein family.

Navitoclax killed senescent cells of several types, among them vein lining cells and lung and mouse embryo fibroblasts, but spared fat precursor cells. A rival blocker, TW-37, did little. Which cells die depends on which survival proteins they lean on. The find widens the toolkit for clearing harmful aged cells.

Catalog record

CREATORZhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB, Wren JD, Niedernhofer LJ, Robbins PD, Kirkland JL.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4854923

Browse the full library · About the Tower of Babel